BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23171216)

  • 1. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology.
    Ma D; Baruch D; Shu Y; Yuan K; Sun Z; Ma K; Hoang T; Fu W; Min L; Lan ZS; Wang F; Mull L; He WW
    BMC Biotechnol; 2012 Nov; 12():88. PubMed ID: 23171216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas.
    Vaezi AE; Bepler G; Bhagwat NR; Malysa A; Rubatt JM; Chen W; Hood BL; Conrads TP; Wang L; Kemp CE; Niedernhofer LJ
    Cancer; 2014 Jun; 120(12):1898-907. PubMed ID: 24692084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297.
    Arbogast S; Behnke S; Opitz I; Stahel RA; Seifert B; Weder W; Moch H; Soltermann A
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):99-105. PubMed ID: 21030862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
    Bahamon BN; Gao F; Danaee H
    Arch Pathol Lab Med; 2016 Dec; 140(12):1397-1403. PubMed ID: 27610644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
    Friboulet L; Olaussen KA; Pignon JP; Shepherd FA; Tsao MS; Graziano S; Kratzke R; Douillard JY; Seymour L; Pirker R; Filipits M; André F; Solary E; Ponsonnailles F; Robin A; Stoclin A; Dorvault N; Commo F; Adam J; Vanhecke E; Saulnier P; Thomale J; Le Chevalier T; Dunant A; Rousseau V; Le Teuff G; Brambilla E; Soria JC
    N Engl J Med; 2013 Mar; 368(12):1101-10. PubMed ID: 23514287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.
    Smith DH; Fiehn AM; Fogh L; Christensen IJ; Hansen TP; Stenvang J; Nielsen HJ; Nielsen KV; Hasselby JP; Brünner N; Jensen SS
    Sci Rep; 2014 Mar; 4():4313. PubMed ID: 24603753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
    Muley TR; Sianidou M; Thomas M; Bischoff H; Dienemann H; Meister M; Schneider MA; Schnabel PA; Warth A
    Anticancer Res; 2014 Jul; 34(7):3707-13. PubMed ID: 24982391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
    Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
    Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment.
    Jagdis A; Phan T; Klimowicz AC; Laskin JJ; Lau HY; Petrillo SK; Siever JE; Thomson TA; Magliocco AM; Hao D
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1340-5. PubMed ID: 23182703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
    Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
    N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin.
    Olaussen KA
    Cancer Biol Ther; 2009 Oct; 8(20):1922-3. PubMed ID: 19713753
    [No Abstract]   [Full Text] [Related]  

  • 13. ERCC1 and non-small-cell lung cancer.
    Niedernhofer LJ; Bhagwat N; Wood RD
    N Engl J Med; 2007 Jun; 356(24):2538-40; author reply 2540-1. PubMed ID: 17568038
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel antibody-based approach to detect the functional ERCC1-202 isoform.
    Kuo MS; Adam J; Dorvault N; Robin A; Friboulet L; Soria JC; Olaussen KA
    DNA Repair (Amst); 2018 Apr; 64():34-44. PubMed ID: 29482102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
    Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
    Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
    Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.